deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02504489

Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC (DUBLIN-3)

Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion

Sponsor: BeyondSpring Pharmaceuticals Inc.

Conditions Non-Small Cell Lung Cancer
Interventions Docetaxel (D) Docetaxel + Plinabulin (DP)
Updated 17 times since 2017 Last updated: Sep 9, 2022 Started: Dec 31, 2015 Primary completion: Mar 23, 2021 Completion: May 23, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02504489, this PHASE3 trial focuses on Non-Small Cell Lung Cancer and remains completed. Sponsored by BeyondSpring Pharmaceuticals Inc., it has been updated 17 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jun 2018 · 14 months · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Jul 2019 · 4 months · monthly snapshot~Jul 2019 – ~Jan 2020 · 6 months · monthly snapshot~Jan 2020 – ~Apr 2020 · 3 months · monthly snapshot~Apr 2020 – ~Aug 2020 · 4 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2022 · 15 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. Jun 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

▶ Show 12 earlier versions

  1. May 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE3

  2. Mar 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  3. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE3

  4. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  5. Apr 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

  6. Jan 2020 — Apr 2020 [monthly]

    Recruiting PHASE3

  7. Jul 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  8. Mar 2019 — Jul 2019 [monthly]

    Recruiting PHASE3

  9. Jun 2018 — Mar 2019 [monthly]

    Recruiting PHASE3

  10. Apr 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

  11. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BeyondSpring Pharmaceuticals Inc.
Data source: BeyondSpring Pharmaceuticals Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Atlanta, United States , Beijing, China , Blacktown, Australia , Bolivar, United States , Chandler, United States , Changchun, China , Changsha, China , Chengdu, China , Cincinnati, United States and 42 more locations